Set the standard for TLS detection
Detect Tertiary Lymphoid Structures across tumor types from digitized H&E slides
Gain insights into a tumor’s interaction with the immune system
A major player in antitumor immune response, the presence of TLS has been associated with improved survival in several tumor types.1
During drug development and clinical trials TLS can serve as a predictive biomarker for response to certain immunotherapies.
Presence of TLS potentially indicates an enhanced immune response making it a possible target for improved response to immunotherapy.2
TLS could guide the development of therapies that target both the tumor cells and the local immune environment.
TLS can support clinical trial optimization, to help better select trial participants to improve success rates across trial phases.
Benefits of TLS detection
As a novel biomarker, TLS presence helps stratify the overall survival risk of untreated cancer patients and helps identify those who may benefit from efficient immunotherapy treatment.
Waiv’s simple and standardized approach could support the adoption of this biomarker as an independent predictor of response to immune checkpoint inhibitors (ICI).
With a sensitivity of 97%, TLS Detect supports the screening for TLS presence across tumors within a research setting.
An automated solution providing standardized quick results
Suitable for tumor specimens across multiple indications
Works with tumor tissue on digitized H&E slides
Externally validated high sensitivity
Researchers in a non-clinical routine setting
Delivered as a PDF with intuitive design
Notes the presence or absence of TLS with score predictions
Determine the status of TLS
Tissue sample is taken and prepared as a H&E slide.
The slide is then digitized.
TLS Detect extracts and analyzes features from the digitized slide.
A PDF report is delivered including a dynamic heat map.
TLS
Presence of TLS, with analysis score provided.
No TLS
No presence of TLS, with analysis score provided.
“As a research tool, TLS Detect has the potential to pre-screen for TLS positive tumor samples, paving the way for optimization of research workflows in multiple tumor indications.”
**97% sensitivity was achieved through validation on an external dataset (n=157 patients)
Citations
- Vanhersecke et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nature Cancer Vol 2 794-802 (Aug 2021)
- Srivastava et al. IMpower110: Tertiary lymphoid structures and clinical outcomes in advanced non-small cell lung cancer treated with first-line atezolizumab or chemotherapy. Presented at The Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. (November 2023).
Legal notice
Manufacturer: Owkin Dx. TLS Detect is a deep learning software, intended to assist researchers in the detection of tertiary lymphoid structures based on digital histology slides.
TLS Detect is for Research Use Only. Not for use in diagnostic procedures.
Information updated on 17th March 2026.